Quantitative Assessment of the Efficacy of Alidya

ALIDYA is a Class III medical device manufactured by Marllor Biomedical (Italy), supplied as a 340 mg lyophilisate dissolved in 10 mL of solvent immediately before administration. The formulation is a polyamino acid gel containing gelatine hydrolysate, mannitol, calcium ascorbate, amino acids, EDTA, β-cyclodextrin, sodium chloride and sodium bicarbonate, and is intended to target the microcirculatory, oedematous, oxidative and fibrotic components of cellulite.

The treatment protocol consisted of six mesotherapy sessions performed at weekly intervals. The preparation was administered using a point-by-point microinjection technique into the dermis or upper subcutaneous layer, to a depth of approximately 4 mm, with a spacing of approximately 1.5 cm between injection sites, delivering 0.05-0.1 mL per point. Total volume per session was adjusted to body weight: 10 mL per session (5 mL per thigh) for participants under 70 kg, and 20 mL per session (10 mL per thigh) for participants 70 kg or over. The treatment area covered the posterior surfaces of both thighs, from approximately 5 cm above the popliteal fossa to the gluteal line.

Assessments were performed at baseline (T1), one month after the first application (T2), and three months after the first application (T3). Clinical assessment used the Nürnberger-Müller scale (C Level). Instrumental assessments included: standardized clinical photography under cross-polarized light with Gray-Level Co-occurrence Matrix (GLCM) texture analysis and Quadtree Decomposition (QTDCOMP) spatial analysis; thermal imaging analyzed via GLCM contrast and homogeneity; hyperspectral imaging (400-1000 nm) with extraction of haemoglobin-, water- and heterogeneity-related spectral metrics; three-dimensional skin surface analysis (Antera 3D) for indentation volume, texture, and erythema; and high-frequency ultrasound (22 MHz) for skin thickness and acoustic density.